Skip to main content

Advertisement

SpringerLink
Log in

A case of Crohn’s disease that developed anti-infliximab and anti-adalimumab antibodies

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

There are few reports about the rapid appearance of anti-adalimumab antibodies in patients with Crohn’s disease positive for anti-infliximab antibodies. We report the case of a 29-year-old female patient with a diagnosis of Crohn’s disease who revealed a loss of response to infliximab due to high levels of antibodies to infliximab, and did not respond to the subsequent therapy by adalimumab, with a rapid appearance of antibodies to adalimumab. As one of the possible mechanisms of non-response to adalimumab, immunologic reactivity of infliximab to adalimumab was suspected, since the patient’s IgG that was obtained just before the induction of adalimumab reacted with infliximab and adalimumab. We should pay attention to the easy appearance of anti-adalimumab antibodies in association with reactivity of anti-infliximab antibodies to adalimumab in patients with high levels of anti-infliximab antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

TNF:

Tumor necrosis factor

IFX:

Infliximab

ADA:

Adalimumab

PVDF:

Polyvinylidene difluoride

ATI:

Anti-infliximab antibody

ATA:

Anti-adalimumab antibody

References

  1. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264–75.

    Article  PubMed  Google Scholar 

  2. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2:542–53.

    Article  CAS  PubMed  Google Scholar 

  3. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56:1226–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628–40.

    Article  CAS  PubMed  Google Scholar 

  5. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685–98.

    Article  CAS  PubMed  Google Scholar 

  6. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2008;28:1122–6.

    Article  CAS  PubMed  Google Scholar 

  7. Chaparro M, Guerra I, Munoz-Linares P, et al. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:971–86.

    Article  CAS  PubMed  Google Scholar 

  8. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol. 2012;47:136–43.

    Article  CAS  PubMed  Google Scholar 

  9. Imaeda H, Bamba S, Takahashi K, et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment. J Gastroenterol. 2014;49:674–82.

    Article  PubMed  Google Scholar 

  10. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460–8.

    Article  CAS  PubMed  Google Scholar 

  12. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–38.

    Article  PubMed  Google Scholar 

  13. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(257–65):e251–3.

    Google Scholar 

  14. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69:817–21.

    Article  CAS  PubMed  Google Scholar 

  15. Frederiksen MT, Ainsworth MA, Brynskov J, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014;20:1714–21.

    Article  PubMed  Google Scholar 

  16. Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease. J Gastroenterol. 2014;49:100–9.

    Article  CAS  PubMed  Google Scholar 

  17. Steenholdt C, Svenson M, Bendtzen K, et al. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn’s disease. J Crohn’s colitis. 2012;6:108–11.

    Article  Google Scholar 

  18. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1250–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (24590940), and a Grant from Intractable Diseases, the Ministry of Health, Labor and Welfare of Japan.

Disclosures

Conflict of Interest: Prof. Akira Andoh served as a lecture speaker for Mitsubishi Tanabe Pharma Co. and Eisai Co. Ltd. Kenichiro Takahashi, Takehide Fujimoto, Makoto Shioya, Atsushi Nishida, Shigeki Bamba, Osamu Inatomi, Hirotsugu Imaeda and Katsuyuki Kitoh declare that they have no conflict of interest.

Human/Animal Rights: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).

Informed consent: Informed consent was obtained from all patients for being included in the study.

Author information

Authors and Affiliations

  1. Department of Medicine, Shiga University of Medical Science, Seta Tsukinowa, Otsu, 520-2192, Japan

    Kenichiro Takahashi, Takehide Fujimoto, Makoto Shioya, Atsushi Nishida, Shigeki Bamba, Osamu Inatomi, Hirotsugu Imaeda, Katsuyuki Kitoh & Akira Andoh

Authors
  1. Kenichiro Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takehide Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Makoto Shioya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atsushi Nishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shigeki Bamba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Osamu Inatomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirotsugu Imaeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katsuyuki Kitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akira Andoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akira Andoh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takahashi, K., Fujimoto, T., Shioya, M. et al. A case of Crohn’s disease that developed anti-infliximab and anti-adalimumab antibodies. Clin J Gastroenterol 8, 88–91 (2015). https://doi.org/10.1007/s12328-015-0558-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-015-0558-y

Keywords

Search

Navigation